Format

Send to

Choose Destination
See comment in PubMed Commons below
Arch Dermatol. 2003 Mar;139(3):301-6.

Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study.

Author information

1
Mayo Medical School, Rochester, MN, USA.

Abstract

OBJECTIVE:

To evaluate the demographic characteristics, clinical course, and outcome in organ transplant recipients with metastatic skin cancer.

DESIGN AND SETTING:

An international, multicenter, Internet-coordinated collaborative group retrospectively analyzed data from 68 organ transplant recipients with 73 distinct metastatic skin cancers.

MAIN OUTCOME MEASUREMENTS:

The Kaplan-Meier method was used to estimate the cumulative incidence of relapse, overall survival, and disease-specific survival after metastatic skin cancer. Univariate Cox proportional hazards models were fit to evaluate factors for an association with survival.

RESULTS:

Metastasis from skin cancer in organ transplant recipients most commonly consisted of squamous cell carcinoma in regional nodal basins. It was predominantly treated with a combination of surgery and irradiation. By 1 year after metastasis, the cumulative incidence of relapse was 29%, and the 3-year disease-specific survival was 56%. Patients whose initial metastases were distant or systemic had a significantly poorer disease-specific survival than those whose initial metastases were in-transit or regional (risk ratio, 6.5; P<.001).

CONCLUSIONS:

Metastatic skin cancer in organ transplant recipients has a poor prognosis. Preventive, early, and aggressive therapeutic interventions are required to minimize this serious complication of transplant-associated immunosuppression.

PMID:
12622621
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center